Amgen reports financial results

Amgen Inc. (NASDAQ:AMGN) reported 4Q11 diluted non-GAAP EPS of $1.21, missing by a penny the Street's estimate of $1.22, but up $0.04 from $1.17 in 4Q10. Revenue for the quarter rose 4% to $4 billion, coming in slightly above the Street's estimate of $3.9 billion. Cost of sales increased 13% to $643 million.

Fourth quarter sales of Xgeva denosumab and Prolia denosumab were $134 million and $81 million, respectively. The products recorded sales of $351 and $203 million, respectively, in 2011 -- the products' first full year on the market since approval in 2010. For the year, Amgen reported diluted non-GAAP EPS of $5.33, up 2% from 2010. Revenue rose 4% to $15.6 billion. ...